Filariasis is a parasitic disease caused by filarial nematodes that are transmitted to humans through blood sucking mosquitoes. There is a symbiotic relationship between the nematodes and the bacterial endosymbiont Wolbachia that makes the nematodes' life cycle heavily dependent on Wolbachia’s presence. Standard therapeutic treatment for filariasis usually involves drug therapy with antiparasitic drugs or the antibiotic doxycycline. However, said treatment has disadvantages such as long therapeutic treatment, and contraindication for children < 8 years and during pregnancy/breast feeding.

Corallopyronin A (CorA) is a non-competitive inhibitor of the bacterial DNA-dependent RNA polymerase. Wolbachia can efficiently be removed by only one or two treatment regimens of CorA.  In addition, side effects were not realised during the pre-clinical studies. A production process of CorA is established on a 15,000 litre scale in preparation for GMP manufacturing. A stable formulation has been developed for oral administration and medical use in logistically difficult regions.